Cargando…

TRAIL Conjugated Silver Nanoparticle Synthesis, Characterization and Therapeutic Effects on HT-29 Colon Cancer Cells

Colon cancer is one of the most prominent causes of cancer-related morbidity and mortality and curable if detected in the early stages. TNF-related apoptosis-inducing ligand (TRAIL) is a therapeutic protein and has a potential anti-cancer activity that is widely used for the treatment of several can...

Descripción completa

Detalles Bibliográficos
Autores principales: Birtekocak, Fatih, Demirbolat, Gulen Melike, Cevik, Ozge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457744/
https://www.ncbi.nlm.nih.gov/pubmed/34567145
http://dx.doi.org/10.22037/ijpr.2020.112069.13514
_version_ 1784571168392478720
author Birtekocak, Fatih
Demirbolat, Gulen Melike
Cevik, Ozge
author_facet Birtekocak, Fatih
Demirbolat, Gulen Melike
Cevik, Ozge
author_sort Birtekocak, Fatih
collection PubMed
description Colon cancer is one of the most prominent causes of cancer-related morbidity and mortality and curable if detected in the early stages. TNF-related apoptosis-inducing ligand (TRAIL) is a therapeutic protein and has a potential anti-cancer activity that is widely used for the treatment of several cancers. In this study, we aimed to develop a silver nanoparticle system conjugated with TRAIL and coated with PEG (AgCTP NPs) to improve the therapeutic effects of colon cancer. AgCTP NPs were characterized by UV spectrum, FTIR and zetasizer. Cytotoxicity, hemolysis assay and apoptotic effects of nanoparticles were investigated using a colon cancer cell line (HT-29) in-vitro. Treatment with AgCTP NPs effectively inhibited proliferation and colony formation of HT-29 cells. The apoptotic effects of nanoparticles on HT-29 cells were determined as Bax, Bcl-2, PARP and clv-PARP protein expression levels using Western blot. Apoptotic proteins were upregulated by AgCTP NPs. In this study, we demonstrated that AgCTP NPs had an anti-cancer effect by activating cell death. Thus, we have confirmed that silver nanoparticles can be selected as a good carrier for TRAIL therapeutic proteins that can be used to treat colon cancer.
format Online
Article
Text
id pubmed-8457744
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Shaheed Beheshti University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-84577442021-09-24 TRAIL Conjugated Silver Nanoparticle Synthesis, Characterization and Therapeutic Effects on HT-29 Colon Cancer Cells Birtekocak, Fatih Demirbolat, Gulen Melike Cevik, Ozge Iran J Pharm Res Original Article Colon cancer is one of the most prominent causes of cancer-related morbidity and mortality and curable if detected in the early stages. TNF-related apoptosis-inducing ligand (TRAIL) is a therapeutic protein and has a potential anti-cancer activity that is widely used for the treatment of several cancers. In this study, we aimed to develop a silver nanoparticle system conjugated with TRAIL and coated with PEG (AgCTP NPs) to improve the therapeutic effects of colon cancer. AgCTP NPs were characterized by UV spectrum, FTIR and zetasizer. Cytotoxicity, hemolysis assay and apoptotic effects of nanoparticles were investigated using a colon cancer cell line (HT-29) in-vitro. Treatment with AgCTP NPs effectively inhibited proliferation and colony formation of HT-29 cells. The apoptotic effects of nanoparticles on HT-29 cells were determined as Bax, Bcl-2, PARP and clv-PARP protein expression levels using Western blot. Apoptotic proteins were upregulated by AgCTP NPs. In this study, we demonstrated that AgCTP NPs had an anti-cancer effect by activating cell death. Thus, we have confirmed that silver nanoparticles can be selected as a good carrier for TRAIL therapeutic proteins that can be used to treat colon cancer. Shaheed Beheshti University of Medical Sciences 2021 /pmc/articles/PMC8457744/ /pubmed/34567145 http://dx.doi.org/10.22037/ijpr.2020.112069.13514 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Birtekocak, Fatih
Demirbolat, Gulen Melike
Cevik, Ozge
TRAIL Conjugated Silver Nanoparticle Synthesis, Characterization and Therapeutic Effects on HT-29 Colon Cancer Cells
title TRAIL Conjugated Silver Nanoparticle Synthesis, Characterization and Therapeutic Effects on HT-29 Colon Cancer Cells
title_full TRAIL Conjugated Silver Nanoparticle Synthesis, Characterization and Therapeutic Effects on HT-29 Colon Cancer Cells
title_fullStr TRAIL Conjugated Silver Nanoparticle Synthesis, Characterization and Therapeutic Effects on HT-29 Colon Cancer Cells
title_full_unstemmed TRAIL Conjugated Silver Nanoparticle Synthesis, Characterization and Therapeutic Effects on HT-29 Colon Cancer Cells
title_short TRAIL Conjugated Silver Nanoparticle Synthesis, Characterization and Therapeutic Effects on HT-29 Colon Cancer Cells
title_sort trail conjugated silver nanoparticle synthesis, characterization and therapeutic effects on ht-29 colon cancer cells
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457744/
https://www.ncbi.nlm.nih.gov/pubmed/34567145
http://dx.doi.org/10.22037/ijpr.2020.112069.13514
work_keys_str_mv AT birtekocakfatih trailconjugatedsilvernanoparticlesynthesischaracterizationandtherapeuticeffectsonht29coloncancercells
AT demirbolatgulenmelike trailconjugatedsilvernanoparticlesynthesischaracterizationandtherapeuticeffectsonht29coloncancercells
AT cevikozge trailconjugatedsilvernanoparticlesynthesischaracterizationandtherapeuticeffectsonht29coloncancercells